Sarepta Therapeutics, Inc.
NEWS
The JP Morgan Health Care Conference is held annually in January, and usually kicks off the biggest biopharma business news stories of the year. But in 2022, it’ll do so without at least three big names in the industry.
It was yet another busy week for clinical trial announcements. Take a look.
Pfizer reported three cases of muscle weakness, two of which involved inflammation of the heart (myocarditis).
Selecta and Cyrus’ partnership will pair Selecta’s immune-modulating ImmTOR platform with Cyrus’ ability to redesign protein therapeutics through its de novo computational approach.
Gene therapy is still very much cutting-edge with the potential to cure incurable genetic diseases. Here’s some recent news in the space.
Sarepta Therapeutics announced its gene therapy candidate, SRP-9001, shows “robust expression and consistent safety profile.”
The Rare Disease Company Coalition’s 10 founding members have brought 22 treatments to market and currently have more than 160 rare disease programs in the works.
Sarepta Therapeutics announced Monday that its next-generation PPMO candidate, SRP-5051, showed promise in a Phase II trial when used as a treatment for Duchenne muscular dystrophy in patients amenable to exon 51 skipping.
JOBS
IN THE PRESS